| 10.885 -0.905 (-7.68%) | 05-04 11:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.37 | 1-year : | 16.79 |
| Resists | First : | 12.31 | Second : | 14.37 |
| Pivot price | 11.08  |
|||
| Supports | First : | 9.57 | Second : | 7.88 |
| MAs | MA(5) : | 11.53 |
MA(20) : | 10.53 |
| MA(100) : | 9.32 |
MA(250) : | 6.31 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 81.6 |
D(3) : | 85.1 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 13.5 | Low : | 2.73 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EKSO ] has closed below upper band by 42.6%. Bollinger Bands are 36% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.32 - 12.39 | 12.39 - 12.44 |
| Low: | 10.83 - 10.9 | 10.9 - 10.96 |
| Close: | 11.67 - 11.79 | 11.79 - 11.9 |
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
Wed, 29 Apr 2026
Ekso Bionics: Q1 Earnings Snapshot - marketscreener.com
Wed, 29 Apr 2026
Ekso Bionics: Q1 Earnings Snapshot - kens5.com
Tue, 28 Apr 2026
Deepening losses push Ekso Bionics (NASDAQ: EKSO) to going concern warning - Stock Titan
Fri, 20 Mar 2026
Ekso Bionics (EKSO) COO Jones buys $15,499 in company stock - Investing.com
Tue, 17 Feb 2026
Ekso Bionics to Combine With Applied Digital Cloud; Issuing 138.2M Shares, Rebrands ChronoScale - TradingView
Mon, 12 Jan 2026
How Recent Developments Are Rewriting The Story For Ekso Bionics Holdings (EKSO) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 4 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 24.5 (%) |
| Held by Institutions | 26.7 (%) |
| Shares Short | 215 (K) |
| Shares Short P.Month | 268 (K) |
| EPS | -5.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.53 |
| Profit Margin | -91.4 % |
| Operating Margin | -119.8 % |
| Return on Assets (ttm) | -33.7 % |
| Return on Equity (ttm) | -107.7 % |
| Qtrly Rev. Growth | -38.3 % |
| Gross Profit (p.s.) | 1.92 |
| Sales Per Share | 3.59 |
| EBITDA (p.s.) | -3.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -2.2 |
| PEG Ratio | 0 |
| Price to Book value | 4.42 |
| Price to Sales | 3.12 |
| Price to Cash Flow | -3.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|